查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085814

流感診斷市場：2026-2032年全球市場預測（按產品類型、檢測類型、檢體類型、技術、檢測方法/實施環境、目標疾病、最終用戶和分銷管道分類）

Influenza Diagnostics Market by Product Type, Test Type, Sample Type, Technology, Mode of Testing / Setting, Disease Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，流感診斷市場將成長至 38.9 億美元，複合年成長率為 10.80%。

主要市場統計數據
基準年 2025 18.9億美元
預計年份：2026年 20.9億美元
預測年份 2032 38.9億美元
複合年成長率 (%) 10.80%

流感診斷正從間歇性的季節性檢測轉向持續的運作感染疾病資訊系統。臨床需求顯而易見。根據世界衛生組織（世衛組織）估計，季節性流感每年導致約10億人感染，其中300萬至500萬例為重症病例，並導致29萬至65萬人死於呼吸道疾病。這些數字表明，流感檢測仍然是急診醫學、基層醫療、小兒科、長期護理、職業健康和公共衛生監測的核心環節。

該市場涵蓋快速流感診斷測試、分子檢測（如RT-PCR和等溫擴增）、多參數呼吸道病原體檢測組合、即時檢測（POC​​）平台以及將檢測結果與治療決策關聯起來的實驗室資訊系統。當臨床醫師需要快速區分甲型流感、乙型流感、SARS-CoV-2、呼吸道合胞病毒（RSV）和其他呼吸道病原體，以確定抗病毒藥物的使用、隔離措施、合理使用抗生素以及醫院容量規劃時，市場需求最為旺盛。

流感檢測領域的變革性變化

最顯著的變化是從單一病原體流感檢測轉向基於症候群的呼吸道疾病診斷。在新冠肺炎疫情期間及之後，醫療系統加速採用多重檢測技術，以便從單一檢體中檢測出流感病毒、SARS-CoV-2、呼吸道合胞病毒（RSV）和其他病原體。這改變了採購行為，檢查室和診所越來越重視工作流程效率、結果報告時間和臨床實用性，而非檢測數量本身。

人工智慧（AI）的累積影響

人工智慧 (AI) 已不再只是產品類型，它正逐漸成為流感診斷整體的實用基礎。 AI 模型有助於疫情預測、規劃檢測需求、最佳化檢查室工作流程以及解讀大規模呼吸道監測資料集。透過與電子健康記錄、基於症候群的監測、天氣模式、流動性指標和歷史陽性率等數據整合，AI 可以幫助醫療系統預測檢測需求高峰，並更有效地分配試劑、人員和設備。

關鍵區域洞察：全球需求趨勢

北美仍然是流感診斷最先進的地區之一，這得益於其強大的檢測能力、美國疾病控制與預防中心 (CDC) 和加拿大公共衛生署建立的完善的監測系統、分子檢測的廣泛應用，以及對臨床必需的呼吸道檢測提供強力的保險報銷。歐洲則受益於國家機構和歐洲疾病預防控制中心 (ECDC) 協調一致的流感監測，其需求由醫院網路、基層醫療哨點監測系統以及檢查室分子診斷平台的良好記錄所支撐。

來自主要區域組織的見解：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協，流感診斷的需求與都市區醫院的擴建、旅行相關監測以及熱帶和亞熱帶氣候地區呼吸道疾病疫情重疊爆發的監測密切相關，因為這些地區的季節性預測往往較為困難。在海灣合作理事會（GCC）國家，對重症患者監護醫院系統、檢查室自動化和衛生安全項目的投資正在穩步推進，多參數呼吸道檢測在急診科、朝聖相關的公共衛生計劃和高階醫療網路中日益受到重視。

重點國家洞察：流感診斷市場領導者

美國在檢測方式的廣度、即時分子診斷的引入以及流感診斷與疾管中心監測和醫療保健系統規程的整合方面處於領先地位。加拿大強調公共衛生報告和各省之間公平的醫療服務獲取，而墨西哥正在透過公立和私立醫療機構擴大快速和分子呼吸道檢測的範圍。巴西擁有強大的全國性監測系統，在南半球流感季期間需求量大。

為行業領導者提供的實用建議

產業領導者應優先考慮兼具速度、準確性和操作便利性的平台。產品系列應涵蓋注重成本效益的快速檢測和高靈敏度的分子檢測，並針對每種醫療場景（家庭和藥房篩檢、急診分流、住院檢測和外包實驗室診斷）進行明確定位。

基於證據的分析的調查方法

本執行摘要基於二手研究和來自權威公共衛生及監管機構的證據整合，包括世界衛生組織流感負擔估計、美國疾病控制與預防中心診斷指南、歐洲疾病預防控制中心監測框架、國家公共衛生機構、同行評審文獻以及公開的監管資訊來源。檢驗重點關注已驗證的流行病學模式、臨床實驗室實踐、技術應用趨勢以及當地醫療基礎設施因素。

結論：流感診斷的未來

流感診斷日益成為呼吸道疾病治療、公共衛生緊急準備和醫療系統效率的關鍵要素。這一領域不再僅限於季節性檢測活動，而是擴大受到分子水平精準性、多重檢測能力、即時檢測部署、數據整合和人工智慧驅動的監測等因素的影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：流感診斷市場：依產品類型分類

  • 檢測套組和試劑
    • RIDT套件
    • PCR試劑組
    • 控制和校準器
  • 設備/分析儀
  • 耗材和配件
    • 拭子
    • 移液器
    • 墨水匣
    • 微孔盤

第8章：流感診斷市場：依檢測類型分類

  • 快速抗原檢測
    • 側向流動檢測
    • 免疫檢測測定
  • 分子檢測
    • RT-PCR單重檢測
    • RT-PCR多重呼吸道檢測
    • 等溫擴增試驗
  • 血清學檢測
    • IgM抗體檢測
    • 總抗體檢測
    • IgG抗體檢測
  • 標準檢驗和高階特性檢驗
    • 基於病毒培養的檢測
    • 基於定序的股票特徵分析與測試
    • 亞型鑑定和監測檢測

第9章：流感診斷市場：依樣本類型分類

  • 鼻咽拭子
  • 支氣管肺泡灌洗（BAL）
  • 口腔和咽拭子
  • 血液/血清拭子
  • 鼻拭子

第10章：流感診斷市場：依技術分類

  • 基於免疫檢測法
    • 酵素免疫分析法
    • 化學冷光免疫檢測
  • 聚合酵素鏈鎖反應
  • 等溫放大技術

第11章：流感診斷市場：依檢測方法/實施環境分類

  • 即時檢測（POC​​T）
  • 臨床試驗
  • 家庭測試

第12章：流感診斷市場：依疾病適應症分類

  • 甲型流感
  • 乙型流感
  • 季節性流感感染疾病
  • 大流行/新型流感

第13章：流感診斷市場：依最終用戶分類

  • 學術研究機構
  • 診所
  • 診斷檢查室
  • 醫院

第14章：流感診斷市場：依通路分類

  • 直銷
  • 銷售代理商和批發商
  • 線上醫療平台

第15章：流感診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：流感診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 流感診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific
  • Siemens Healthineers AG
  • Qiagen NV
  • Becton, Dickinson and Company
  • Seegene, Inc.
  • DiaSorin SpA
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Cocrystal Pharma, Inc.
  • Visby Medical, Inc.
  • Access Bio, Inc.
  • ACON Laboratories, Inc.
  • Bioneer Corporation
  • CSL Limited
  • GenBody Inc.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Jiangsu Bioperfectus Technologies Co., Ltd.
  • NATCO Pharma Limited
  • Novacyt SA
  • Novartis AG
  • R-Biopharm AG
  • Sansure Biotech Inc.
  • Shionogi & Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vircell, SL
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-43127F72796F

The Influenza Diagnostics Market is projected to grow by USD 3.89 billion at a CAGR of 10.80% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.89 billion
Estimated Year [2026] USD 2.09 billion
Forecast Year [2032] USD 3.89 billion
CAGR (%) 10.80%

Influenza diagnostics are moving from episodic seasonal testing toward always-on respiratory infection intelligence. The clinical need is clear: the World Health Organization estimates that seasonal influenza causes about 1 billion infections annually, including 3 to 5 million severe cases and 290,000 to 650,000 respiratory deaths. These figures keep influenza testing central to emergency care, primary care, pediatrics, long-term care, occupational health, and public health surveillance.

The market is shaped by rapid influenza diagnostic tests, molecular assays such as RT-PCR and isothermal amplification, multiplex respiratory panels, point-of-care platforms, and laboratory information systems that connect test results to treatment decisions. Demand is strongest where clinicians need fast differentiation between influenza A, influenza B, SARS-CoV-2, RSV, and other respiratory pathogens to guide antiviral use, isolation, antibiotic stewardship, and hospital capacity planning.

Transformative Shifts in the Influenza Testing Landscape

The most important shift is the move from single-pathogen flu testing to syndromic respiratory diagnostics. During and after the COVID-19 pandemic, health systems accelerated adoption of multiplex assays that detect influenza, SARS-CoV-2, RSV, and other pathogens from one specimen. This has changed purchasing behavior, with laboratories and clinics increasingly prioritizing workflow efficiency, result turnaround time, and clinical actionability over test volume alone.

A second shift is the expansion of point-of-care molecular diagnostics. Traditional rapid antigen tests remain useful because they are inexpensive and can deliver results in minutes, but CDC guidance has long noted that rapid influenza diagnostic tests generally have lower sensitivity than molecular methods. As a result, near-patient molecular platforms are gaining importance in urgent care, emergency departments, pharmacies, and decentralized care settings where speed and accuracy both matter.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer across influenza diagnostics rather than a standalone product category. AI models support outbreak forecasting, test demand planning, laboratory workflow triage, and interpretation of large respiratory surveillance datasets. When linked with electronic health records, syndromic surveillance, weather patterns, mobility indicators, and historical positivity rates, AI can help health systems anticipate testing peaks and allocate reagents, staff, and instruments more efficiently.

AI also strengthens diagnostic operations by improving quality control, automating result review, and flagging unusual positivity patterns that may indicate localized outbreaks or specimen handling issues. The greatest near-term value is expected in decision support: combining test results with symptoms, exposure history, vaccination status, and local influenza activity to guide antiviral prescribing and infection control. Adoption will depend on validation, transparency, cybersecurity, and regulatory alignment.

Key Regional Insights: Global Demand Patterns

North America remains one of the most advanced influenza diagnostics regions due to high laboratory capacity, established CDC and Public Health Agency of Canada surveillance systems, broad use of molecular testing, and strong reimbursement pathways for clinically necessary respiratory testing. Europe benefits from coordinated influenza monitoring through national agencies and ECDC-linked surveillance, with demand supported by hospital networks, primary care sentinel systems, and a strong installed base of laboratory molecular platforms.

Asia-Pacific is a highly dynamic environment because of large population scale, recurring influenza burden, expanding hospital infrastructure, and government investment in infectious disease preparedness after COVID-19 and avian influenza concerns. China, Japan, India, South Korea, Australia, and ASEAN markets are expanding use of rapid and molecular respiratory testing at different speeds depending on reimbursement, access, and local manufacturing capacity.

Latin America, the Middle East, and Africa present rising opportunities as governments strengthen respiratory disease surveillance and decentralized diagnostics. Brazil and Mexico anchor Latin American demand, while GCC health systems invest in advanced hospital diagnostics and digital health. Across Africa, demand is supported by the need for scalable point-of-care testing, but adoption is constrained by affordability, procurement fragmentation, cold-chain logistics, and uneven access to molecular laboratories.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

In ASEAN, influenza diagnostics demand is tied to urban hospital expansion, travel-related surveillance, and the need to monitor overlapping respiratory outbreaks in tropical and subtropical climates where seasonality can be less predictable. The GCC is investing in high-acuity hospital systems, laboratory automation, and health security programs, making multiplex respiratory testing attractive for emergency departments, pilgrimage-related public health planning, and premium care networks.

The European Union supports a mature diagnostics environment through harmonized regulatory expectations, strong laboratory networks, and cross-border disease monitoring. BRICS countries represent high-volume demand because Brazil, Russia, India, China, and South Africa combine large patient populations with growing domestic diagnostics manufacturing and government-led infectious disease programs.

G7 markets are characterized by advanced reimbursement systems, early adoption of molecular and multiplex platforms, and strong clinical guideline influence. NATO countries, while not a healthcare bloc, increasingly view infectious disease readiness as part of resilience planning, supporting demand for diagnostics that can operate reliably across civilian, military, and emergency response settings.

Key Country Insights: Leading Influenza Diagnostics Markets

The United States leads in test menu breadth, point-of-care molecular adoption, and integration of influenza diagnostics with CDC surveillance and health system protocols. Canada emphasizes public health reporting and equitable access across provinces, while Mexico is expanding rapid and molecular respiratory testing through public and private providers. Brazil has strong national surveillance infrastructure and significant demand during Southern Hemisphere influenza seasons.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature demand for laboratory-based molecular testing, hospital respiratory panels, and primary care surveillance. Germany and France benefit from strong laboratory networks; the United Kingdom has advanced public health analytics; Italy and Spain have significant hospital demand during seasonal surges. Russia maintains demand through public sector hospital systems and domestic diagnostics capacity.

In Asia-Pacific, China is a major volume market with expanding molecular testing infrastructure and government focus on respiratory pathogen monitoring. India combines high disease burden with growing private diagnostics chains and a need for affordable rapid testing. Japan and South Korea are advanced adopters of high-quality diagnostics, automation, and surveillance-linked testing. Australia benefits from strong seasonal monitoring, public health reporting, and established use of molecular respiratory assays.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that combine speed, accuracy, and operational simplicity. Product portfolios need to cover both cost-sensitive rapid testing and higher-sensitivity molecular options, with clear positioning by care setting: home and pharmacy screening, urgent care triage, hospital admission testing, and reference laboratory confirmation.

Organizations should invest in multiplex respiratory panels that remain clinically focused and economically defensible. Overly broad panels may face reimbursement scrutiny, while targeted influenza, RSV, and SARS-CoV-2 combinations align closely with real-world clinical decisions. Partnerships with public health agencies, hospital networks, and digital surveillance platforms can strengthen access and demonstrate measurable value.

Manufacturers should also localize strategies by region. In mature markets, differentiation should center on turnaround time, connectivity, automation, and health-economic evidence. In emerging markets, affordability, rugged instruments, simplified procurement, training, and reliable reagent supply are decisive.

Research Methodology for Evidence-Based Analysis

This executive summary is based on secondary research and evidence synthesis from recognized public health and regulatory sources, including WHO influenza burden estimates, CDC diagnostic guidance, ECDC surveillance frameworks, national public health agencies, peer-reviewed literature, and publicly available regulatory information. The analysis emphasizes verified epidemiological patterns, clinical testing practices, technology adoption trends, and regional healthcare infrastructure factors.

The methodology combines qualitative assessment of industry drivers with comparative evaluation of diagnostic modalities, including rapid antigen tests, RT-PCR, isothermal molecular assays, multiplex panels, point-of-care platforms, and digital surveillance tools. Insights were reviewed for consistency with established clinical guidance and current respiratory disease preparedness priorities.

Conclusion: The Future of Influenza Diagnostics

Influenza diagnostics are becoming a strategic component of respiratory care, public health preparedness, and healthcare system efficiency. The field is no longer defined only by seasonal testing activity; it is increasingly shaped by molecular accuracy, multiplex capability, point-of-care deployment, data connectivity, and AI-enabled surveillance.

Organizations that align testing solutions with clinical workflows, reimbursement realities, and regional access needs will be well positioned for durable relevance. As influenza continues to overlap with RSV, COVID-19, and emerging respiratory threats, reliable diagnostics will remain essential for timely treatment, outbreak control, and informed health policy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Influenza Diagnostics Market, by Product Type

  • 7.1. Test Kits & Reagents
    • 7.1.1. RIDT Kits
    • 7.1.2. PCR Reagent Kits
    • 7.1.3. Controls & Calibrators
  • 7.2. Instruments / Analyzers
  • 7.3. Consumables & Accessories
    • 7.3.1. Swabs
    • 7.3.2. Pipettes
    • 7.3.3. Cartridges
    • 7.3.4. Microplates

8. Influenza Diagnostics Market, by Test Type

  • 8.1. Rapid Antigen Tests
    • 8.1.1. Lateral Flow Tests
    • 8.1.2. Immunoassay Tests
  • 8.2. Molecular Tests
    • 8.2.1. RT-PCR Singleplex Tests
    • 8.2.2. RT-PCR Multiplex Respiratory Tests
    • 8.2.3. Isothermal Amplification Tests
  • 8.3. Serology Tests
    • 8.3.1. IgM Antibody Tests
    • 8.3.2. Total Antibody Tests
    • 8.3.3. IgG Antibody Tests
  • 8.4. Reference & Advanced Characterization Tests
    • 8.4.1. Viral Culture-Based Tests
    • 8.4.2. Sequencing-Based Strain Characterization Tests
    • 8.4.3. Subtyping And Surveillance Assays

9. Influenza Diagnostics Market, by Sample Type

  • 9.1. Nasopharyngeal Swabs
  • 9.2. Bronchoalveolar Lavage (BAL)
  • 9.3. Oropharyngeal Swabs
  • 9.4. Blood/serum Swabs
  • 9.5. Nasal Swabs

10. Influenza Diagnostics Market, by Technology

  • 10.1. Immunoassay-Based
    • 10.1.1. Enzyme Immunoassay
    • 10.1.2. Chemiluminescent Immunoassay
  • 10.2. Polymerase Chain Reaction
  • 10.3. Isothermal Amplification Technologies

11. Influenza Diagnostics Market, by Mode of Testing / Setting

  • 11.1. Point-of-Care Testing (POCT)
  • 11.2. Laboratory Testing
  • 11.3. Home-Based Testing

12. Influenza Diagnostics Market, by Disease Indication

  • 12.1. Influenza A
  • 12.2. Influenza B
  • 12.3. Seasonal Influenza infections
  • 12.4. Pandemic / Novel Influenza

13. Influenza Diagnostics Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Clinics
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals

14. Influenza Diagnostics Market, by Distribution Channel

  • 14.1. Direct Sales
  • 14.2. Distributors & Wholesalers
  • 14.3. Online Medical Platforms

15. Influenza Diagnostics Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Influenza Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Influenza Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. F. Hoffmann-La Roche Ltd.
  • 19.3. QuidelOrtho Corporation
  • 19.4. Thermo Fisher Scientific
  • 19.5. Siemens Healthineers AG
  • 19.6. Qiagen N.V.
  • 19.7. Becton, Dickinson and Company
  • 19.8. Seegene, Inc.
  • 19.9. DiaSorin S.p.A.
  • 19.10. Hologic, Inc.
  • 19.11. Agilent Technologies, Inc.
  • 19.12. Bio-Rad Laboratories, Inc.
  • 19.13. Guangzhou Wondfo Biotech Co., Ltd.
  • 19.14. Cocrystal Pharma, Inc.
  • 19.15. Visby Medical, Inc.
  • 19.16. Access Bio, Inc.
  • 19.17. ACON Laboratories, Inc.
  • 19.18. Bioneer Corporation
  • 19.19. CSL Limited
  • 19.20. GenBody Inc.
  • 19.21. Hangzhou AllTest Biotech Co., Ltd.
  • 19.22. Jiangsu Bioperfectus Technologies Co., Ltd.
  • 19.23. NATCO Pharma Limited
  • 19.24. Novacyt S.A.
  • 19.25. Novartis AG
  • 19.26. R-Biopharm AG
  • 19.27. Sansure Biotech Inc.
  • 19.28. Shionogi & Co., Ltd.
  • 19.29. Teva Pharmaceutical Industries Ltd.
  • 19.30. Vircell, S.L.
  • 19.31. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TEST KITS & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TEST KITS & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TEST KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RIDT KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RIDT KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RIDT KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PCR REAGENT KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PCR REAGENT KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PCR REAGENT KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSTRUMENTS / ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSTRUMENTS / ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSTRUMENTS / ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PIPETTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PIPETTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PIPETTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROPLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICROPLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICROPLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RAPID ANTIGEN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RAPID ANTIGEN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RAPID ANTIGEN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LATERAL FLOW TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LATERAL FLOW TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LATERAL FLOW TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOASSAY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOASSAY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOASSAY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RT-PCR SINGLEPLEX TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RT-PCR SINGLEPLEX TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RT-PCR SINGLEPLEX TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RT-PCR MULTIPLEX RESPIRATORY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RT-PCR MULTIPLEX RESPIRATORY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RT-PCR MULTIPLEX RESPIRATORY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEROLOGY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEROLOGY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEROLOGY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IGM ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IGM ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IGM ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOTAL ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOTAL ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TOTAL ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IGG ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IGG ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IGG ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL REFERENCE & ADVANCED CHARACTERIZATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL REFERENCE & ADVANCED CHARACTERIZATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL REFERENCE & ADVANCED CHARACTERIZATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL CULTURE-BASED TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL CULTURE-BASED TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL CULTURE-BASED TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEQUENCING-BASED STRAIN CHARACTERIZATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SEQUENCING-BASED STRAIN CHARACTERIZATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEQUENCING-BASED STRAIN CHARACTERIZATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBTYPING AND SURVEILLANCE ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUBTYPING AND SURVEILLANCE ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBTYPING AND SURVEILLANCE ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OROPHARYNGEAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OROPHARYNGEAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OROPHARYNGEAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD/SERUM SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD/SERUM SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD/SERUM SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NASAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NASAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NASAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOASSAY-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOASSAY-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOASSAY-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENZYME IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENZYME IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENZYME IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ISOTHERMAL AMPLIFICATION TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ISOTHERMAL AMPLIFICATION TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ISOTHERMAL AMPLIFICATION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POINT-OF-CARE TESTING (POCT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT-OF-CARE TESTING (POCT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POINT-OF-CARE TESTING (POCT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOME-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOME-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOME-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SEASONAL INFLUENZA INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SEASONAL INFLUENZA INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SEASONAL INFLUENZA INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PANDEMIC / NOVEL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PANDEMIC / NOVEL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PANDEMIC / NOVEL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DIRECT SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIRECT SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DIRECT SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DISTRIBUTORS & WHOLESALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DISTRIBUTORS & WHOLESALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DISTRIBUTORS & WHOLESALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ONLINE MEDICAL PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONLINE MEDICAL PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ONLINE MEDICAL PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 277. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 278. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 280. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 283. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 284. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 322. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 323. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 325. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 326. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 327. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 328. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 331. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 332. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 333. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 335. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 339. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 341. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 342. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 343. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 344. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
  • TABLE 347. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
  • TABLE 348. NATO INF